Assessment of Inflammatory mediator release, microvascular resistance, and plaque morphology after percutaneous coronary intervention in patients treated with colchicine.

Not Applicable

Recruiting

• Conditions: coronary artery disease; acute coronary syndrome; stable coronary artery disease; Cardiovascular - Coronary heart disease

• Registration Number: ACTRN12619001449123
• Lead Sponsor: The Heart Research Institute

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2019-10-18
• Last Update Posted: 7 June 2021

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 25

Inclusion Criteria

Inclusion Criteria: Patients (>21yrs) with a clinical need for cardiac catheterisation at Royal
Prince Alfred Hospital will be invited to participate in the study.

Exclusion Criteria

Patients with greater than 50% stenosis in the left main coronary artery, cardiogenic shock or haemodynamic instability will be excluded from the study. Other exclusion criteria include age <21, pregnancy, those unable to make their own decisions, patients with moderate renal dysfunction (creatinine clearance <50 ml/min) or hepatic dysfunction (ALT [1.5 x upper limit of normal range); thrombocytopenia or leukopenia; pregnant or lactating women and women at risk of pregnancy. Patients already taking colchicine, those with evidence of active infection or inflammatory conditions that might be associated with markedly elevated hs-CRP levels in the blood (e.g., active rheumatoid arthritis) and those taking other anti-inflammatory therapies (e.g. corticosteroids) or strong CYP3A4 inhibitors will also be excluded.

Study & Design

• Study Type: Interventional
• Study Design: Not specified